A 54 year old diabetes patient from Pontefract has expressed his thanks after taking part in a research trial at The Mid Yorkshire Hospitals NHS Trust which saved his foot from amputation.
Philip Herbert, who was diagnosed with type 2 diabetes in 2007 and later developed an ulcer on his foot, was part of the device trial called “LeucoPatch® in the Management of Hard-to-heal Diabetic Foot Ulcers.“
LeucoPatch® is produced from the patient’s own blood by a process called centrifugation. The final product comprises a thin circular plug composed of high concentrated fibrin (a protein formed during the clotting of blood) as well as platelets and leucocytes (white blood cells).
This plug is used as a dressing for the diabetic foot ulcer and applied weekly in clinic. After six weeks Philip’s wound had completely healed.
“The LeucoPatch® was absolutely amazing,” said Philip, “I’d been told that I was going to have to have my foot taken off and because I have a metal plate in my ankle it would have meant amputating at the knee. I’m a self-employed mechanic and driver so losing part of a leg would have had a tremendous effect on my life.”
Specialist Podiatrist, Nicola Murphy, who has been treating him for his diabetic foot ulcer, suggested putting Philip forward for the trial. “Philip had the ulcer for over a year and even though we were doing all we could to help it heal it just wouldn’t. I didn’t want him to lose his foot so I suggested the trial to him.
Diabetes Research Nurse, Mymy Del Rosario who managed the trial was very pleased with the outcome. “I’m so happy he agreed to take part in the study, particularly as he has a fear of needles and we needed to take his blood weekly. His trial participation has not only healed his wound, but it has greatly benefited his quality of life. It couldn’t have gone better.”
Philip continues to attend the diabetic foot clinic on a regular basis to ensure any other ulcers which develop are treated accordingly. The Trust is now doing a post-trial evaluation and has just identified its first patient who will be treated with the patch as part of standard care.
Dr Ryan D'Costa, the study’s Principle Investigator at The Mid Yorkshire Hospitals NHS Trust, said: “The results of this clinical trial speak for themselves. Saving Mr Herbert’s foot is without doubt the best outcome we could have hoped for.
“Being involved in clinical research is extremely important to both us as a trust and the future of medicine. It enables us to give our patients access to new treatments whilst helping to explore the development of new ones.”
Notes to editors
- Denmark based Reapplix is the organisation behind the development of LeucoPatch®. As the product moves nearer to market, following successful trials, it will be known as the 3C Patch.
- LeucoPatch® is prepared by centrifuging one or more 18ml aliquots of the participant's venous blood in the LeucoPatch® device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
- Research is an integral part of our work at the Trust, and forms part of our strategic objectives (objective 6 of our Strategic Plan is to...Provide Excellent Research, Development and Innovation opportunities). It helps us to turn promising ideas or interesting theories into real benefits for our patients and members of the local community. We conduct research into common diseases that affect large numbers of people acknowledged as global health challenges, such as respiratory and cardiovascular disease, cancer and diabetes. We also conduct research into rare conditions which affect individuals and families.
- The Trust currently has more than 200 research projects running supported by more than 40 members of staff.
- The research study was sponsored by Nottingham University Hospitals Trust .